24091-92-7

Basic information

• Product Name: 2'-Bromo-4-chlorophenylacetic acid methyl ester
• Synonyms: 2-BROMO-4-CHLOROPHENYLACETIC ACID METHYL ESTER;Methyl-2-bromo-4-chlorophenylacetate;2-(2-broMo-4-chlorophenyl)propanoate;Methyl 2-broMo-2-(4-chlorophenyl)acetate;Methyl a-broMo-4-chlorophenylacetate;Benzeneacetic acid, .alpha.-bromo-4-chloro-, methyl ester
• CAS NO: 24091-92-7
• Molecular Formula: C₉H₈BrClO₂
• Molecular Weight: 263.52
• EINECS: 200-258-5
• Product Categories: Aromatic Esters
• Mol File: 24091-92-7.mol
• Article Data: 34

Chemical Properties

• Boiling Point: 149-152 °C(Press: 16 Torr)
• Appearance: /
• Density: 1.567±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2'-Bromo-4-chlorophenylacetic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2'-Bromo-4-chlorophenylacetic acid methyl ester(24091-92-7)
• EPA Substance Registry System: 2'-Bromo-4-chlorophenylacetic acid methyl ester(24091-92-7)

Safety Data

• RIDADR: 1760
• HazardClass: 8
• PackingGroup: Ⅲ
• Hazardous Substances Data: 24091-92-7(Hazardous Substances Data)

Usage

General Description

2'-Bromo-4-chlorophenylacetic acid methyl ester is a chemical compound that belongs to the family of esters. It is derived from the combination of 2'-bromo-4-chlorophenylacetic acid and methyl alcohol. 2'-Bromo-4-chlorophenylacetic acid methyl ester is commonly used in organic synthesis and pharmaceutical research. It is known for its potential applications in the development of medications and as a building block in the production of various drugs. Additionally, it is used in the production of agrochemicals and as an intermediate in the manufacturing of other chemical products. The compound is also a useful reagent in the synthesis of complex organic compounds.

Upstream product

• 25026-34-0 4-chlorophenacetyl chloride 
• 67-56-1 methanol 
• 33512-03-7 3-(4-chlorophenyl)oxirane-2,2-dicarbonitrile 
• 52449-43-1 (4-chloro-phenyl)-acetic acid methyl ester 
• 3381-73-5 2-bromo-2-(4-chlorophenyl)acetic acid 
• 32174-34-8 methyl 4-chloromandelate 
• 1878-66-6 4-chlorophenylacetic Acid 
• 7138-34-3 p-chloromandelic acid 
• 104-88-1 4-chlorobenzaldehyde 
• 1867-38-5 4-chlorobenzylidenemalonodinitrile 

Downstream Products

• 51856-32-7 5-(4-Chloro-phenyl)-2-imino-thiazolidin-4-one 
• 114898-40-7 methyl 2-(acetylthio)-2-(4-chlorophenyl)acetate 
• 787633-99-2 (R,S)-α-(4-chlorophenyl)-α-[(R)-N-[1-(4-chlorophenyl)ethyl]amino]acetic acid methyl ester 
• 851664-11-4 (4-Chloro-phenyl)-{[(R)-1-(4-chloro-phenyl)-ethyl]-[(E)-(3-phenyl-acryloyl)]-amino}-acetic acid methyl ester 
• 851664-13-6 (4-Chloro-phenyl)-{[(R)-1-(4-chloro-phenyl)-ethyl]-[(E)-(3-phenyl-acryloyl)]-amino}-acetic acid 
• 787633-77-6 (3S)-1,3-dihydro-3-(4-chlorophenyl)-4-[(R)-1-(4-chlorophenyl)ethyl]-7-phenyl-1,4-diazepine-2,5-dione 
• 851664-12-5 {[(E)-3-(2-Bromo-phenyl)-acryloyl]-[(R)-1-(4-chloro-phenyl)-ethyl]-amino}-(4-chloro-phenyl)-acetic acid methyl ester 
• 851664-14-7 {[(E)-3-(2-Bromo-phenyl)-acryloyl]-[(R)-1-(4-chloro-phenyl)-ethyl]-amino}-(4-chloro-phenyl)-acetic acid 
• 851664-18-1 (S)-7-(2-Bromo-phenyl)-3-(4-chloro-phenyl)-4-[(R)-1-(4-chloro-phenyl)-ethyl]-3,4-dihydro-1H-[1,4]diazepine-2,5-dione 
• 787633-76-5 (3S)-1,3,6,7-tetrahydro-3-(4-chlorophenyl)-4-[(R)-1-(4-chlorophenyl)ethyl]-7-phenyl-6-(phenylseleno)-1,4-diazepine-2,5-dione 
• 851664-17-0 (S)-7-(2-Bromo-phenyl)-3-(4-chloro-phenyl)-4-[(R)-1-(4-chloro-phenyl)-ethyl]-6-phenylselanyl-[1,4]diazepane-2,5-dione 

Relevant articles and documents

Extensive investigation of benzylic N-containing substituents on the pyrrolopyrimidine skeleton as Akt inhibitors with potent anticancer activity

Continuous optimization of benzylic substituents on 1-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperazin-1-yl)-2-phenylethan-1-one structure as Akt inhibitors was described in this paper. Particularly, compounds 8 and 14g exhibited high enzymatic potency against all Akt isoforms and antiproliferative effects in mantle cell lymphoma cell lines, as well as favorable cytotoxicities in patient primary cancer cells. Low micromolar doses of both 8 and 14g dose-dependently induced cell apoptosis and G2/M cell cycle arrest, also suppressed the phosphorylation level of Akt downstream targets GSK3β and S6.

Development of indazole mineralocorticoid receptor antagonists and investigation into their selective late-stage functionalization

The derivatization of pharmaceuticals is a core activity in the discovery and development of new medicines. Late-stage functionalization via modern C–H functionalization chemistry has emerged as a powerful technique with which to diversify advanced pharma